--------------------
continue
AVGs
AVFs
AVGs
AVFs
pharmacomechanical
rheolytic
AVGs
AVFs
--------------------
human
65–85
hemoconcentration
Cannulation
REF].Thrombosed
Thrombus
Thrombosed
--------------------
create
Thrombosed
AVGs
AVFs
Embolectomy
rheolytic
AVGs
AVFs
--------------------
explain
AVFs
AVGs
AVGs
AVFs
--------------------
human
disease-2019
78%.5
CSDH)8
--------------------
continue
--------------------
explain
--------------------
create
disease-2019
--------------------
human
immunoregulation
eATP
eATP
eATP
purinoceptor
eATP
eADO
ectonucleotidases
REF].eADO
signaling.eADO
eATP
ectonucleotidases
eATP
CD39
ectonucleoside
diphosphohydrolase
eADO
CD73
5′-nucleotidase
eAMP
eADO
eAMP
eATP
NDPK
REF].The
eADO
ectohydrolase
CD203a
ectonucleotide
--------------------
explain
eADO
eATP
eATP
eATP
purinoceptor
eATP
eADO
ectonucleotidases
eADO
CD39
ectonucleoside
diphosphohydrolase
CD73
5'-nucleotidase
eADO
ectohydrolase
CD203a
ectonucleotide
eADO
eADO
CD39
CD73
eADO
--------------------
create
eADO
eADO
eATP
eATP
eADO
eATP
eADO
adenosinergic
adenosinergic
adenosinergic
adenosinergic
--------------------
continue
adenosinergic
eADO
eADO
eATP
eATP
eATP
eADO
eADO
eATP
eADO
adenosinergic
adenosinergic
adenosinergic
eADO
adenosinergic
eADO
adenosinergic
--------------------
human
REF]).Detailed
sarcopenic
--------------------
continue
Jentoft
AgeiNg
ENHANce
aLM
aLM
SarQoL
sarcopenic
--------------------
create
Jentoft
Gammone
Simopoulos
AgeiNg
ENHANce
SarQoL
ENHANce
sarcopenic
--------------------
explain
sarcopenic
--------------------
create
immunopathological
--------------------
human
PASC.The
https://recovercovid.org/protocols
PASC.The
--------------------
explain
Biospecimens
--------------------
continue
immunopathological
immunopathological
